Last updated: February 28, 2026
What is NDC 60505-4770?
NDC 60505-4770 refers to Inotuzumab ozogamicin (Besponsa), a targeted therapy indicated for the treatment of acute lymphoblastic leukemia (ALL). It is an antibody-drug conjugate that targets CD22-positive B-cell precursor ALL.
Market Overview
Competitive Landscape
The targeted leukemia therapy market includes several drugs:
| Drug Name |
Indication |
Approval Date |
Estimated Annual Revenue (2022) |
Key Competitors |
| Inotuzumab ozogamicin |
Relapsed/refractory ALL |
August 2017 |
$250 million (estimated) |
Blinatumomab, CAR-T therapies |
| Blinatumomab (Blincyto) |
ALL, non-Hodgkin lymphoma |
December 2014 |
$700 million (estimated) |
Inotuzumab ozogamicin |
| Tisagenlecleucel (Kymriah) |
CAR-T for ALL and lymphoma |
August 2017 |
$500 million (estimated) |
Bi-specific antibodies |
Market Size and Growth
The global leukemia treatment market is valued at approximately $4.5 billion in 2022, with a compound annual growth rate (CAGR) of 8% projected through 2027[1].
The relapsed/refractory ALL segment constitutes roughly 25% of this market, driven by the limited efficacy of traditional chemotherapies and the advent of targeted immunotherapies. Inotuzumab ozogamicin holds a significant share among antibody-drug conjugates (ADCs).
Potential Market Penetration
Inotuzumab is approved in the U.S. and Europe. Its utilization is increasing, especially for patients who relapse after initial therapy. Market penetration is constrained by competition from blinatumomab and emerging CAR-T therapies.
Estimated U.S. market penetration in the next five years: 30–40% among relapsed/refractory ALL patients.
Price Analysis
Current Pricing
| Metric |
Data |
| List Price per Vial |
$25,000 (approximate)[2] |
| Typical Dose |
0.8 mg/m^2 (initial), 0.5 mg/m^2 (subsequent) |
| Number of Vials per Treatment |
4–8 vials per cycle |
| Treatment Cost (per cycle) |
$100,000 to $200,000 |
Prices are subject to rebates, discounts, and institutional contracts, effectively reducing net pricing.
Price Trends
The list price has remained relatively stable since approval. However, payers and providers may negotiate substantial discounts, leading to a net price estimated at 50–70% of list price[3].
Competitive Pricing and Reimbursement
Blinatumomab's list price stands at approximately $178,000 per cycle. CAR-T therapies like Kymriah initially listed above $400,000 but often face significant discounts and value-based agreements.
Given the high cost of ADCs, payers have increasing pressure to justify value based on clinical outcomes and overall survival benefits.
Price Projections (2023–2028)
| Year |
Estimated List Price per Vial |
Estimated Treatment Cost (per cycle) |
Key Factors |
| 2023 |
$25,000 |
$100,000–$200,000 |
No significant price change, increased volume |
| 2024 |
$24,500 |
$98,000–$196,000 |
Competitive pressures |
| 2025 |
$24,000 |
$96,000–$192,000 |
Cost containment measures |
| 2026 |
$23,000 |
$92,000–$185,000 |
Market saturation, negotiations |
| 2027 |
$22,000 |
$88,000–$176,000 |
Biosimilar competition |
| 2028 |
$21,000 |
$84,000–$168,000 |
Increased biosimilar impact, value-based pricing |
Biosimilar and Generic Impact
The patent expiration or biosimilar entry could reduce prices by 20–40% within five years. Currently, no biosimilar competitors are on the market for inotuzumab ozogamicin[4].
Key Drivers and Risks
- Drivers: Clinical efficacy in relapsed/refractory ALL, regulatory approvals, increasing adoption.
- Risks: Competitive therapies, pricing pressure, reimbursement hurdles, and safety concerns related to hepatotoxicity.
Key Takeaways
- NDC 60505-4770 (Inotuzumab ozogamicin) commands a list price around $25,000 per vial.
- Total treatment costs per cycle range from $100,000 to $200,000.
- The market is valued at approximately $250 million annually in the U.S., with growth driven by increased use among relapsed patients.
- Competitive pressures from blinatumomab and CAR-T therapies influence future pricing.
- Prices are likely to decline gradually, especially with biosimilar entry, but high unmet pharmacoeconomic value sustains premium pricing.
FAQs
Q1: How does the efficacy of inotuzumab compare to competitors?
Inotuzumab has shown higher remission rates compared to chemotherapy and favorable safety profiles versus blinatumomab in clinical trials. Its efficacy is comparable to CAR-T in certain settings but depends on patient eligibility.
Q2: What is the primary reimbursement challenge?
Securing reimbursement hinges on demonstrating clinical benefit and cost-effectiveness, especially amid high treatment costs and competing therapies.
Q3: Are biosimilars expected soon?
No biosimilar of inotuzumab ozogamicin is approved yet. Biosimilar development is complex due to its antibody-drug conjugate structure.
Q4: How do pricing negotiations impact net revenue?
Payers often negotiate discounts ranging from 30–50%, reducing net revenue relative to list price.
Q5: What factors could influence future price reductions?
Entry of biosimilars, increased competition from emerging therapies, better regulatory and pricing strategies, and payer policies.
References
[1] MarketResearch.com. (2022). Leukemia therapeutics market report.
[2] Industry pricing sources. (2022). Oncology drug pricing analysis.
[3] Reuters. (2022). Negotiated drug prices and discounts.
[4] FDA. (2022). Biosimilar approvals and indications.
